Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Qi Microbial Technology is a clinical-stage biotechnology company based in Zhuhai, China, specializing in the development of live biotherapeutic products (LBPs). The company focuses on the "skin-gut axis" and "gut-brain axis" to create innovative treatments for immune-mediated and metabolic disorders. Its lead candidate, QY001, is a first-in-class microbial therapy currently in Phase 2 clinical trials for atopic dermatitis. By leveraging proprietary strain screening and stabilization technologies, Qi Microbial aims to translate microbiome research into standardized, effective pharmaceutical interventions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhuhai Qi Microbial Technology.